Expand all sections

LN-144 (TIL)

Contego

Extended indication Maliganant melanoma, advanced melanoma
Therapeutic value No judgement
Registration phase Clinical trials

Product

Active substance LN-144 (TIL)
Domain Oncology and Hematology
Main indication Skin cancer
Extended indication Maliganant melanoma, advanced melanoma
Proprietary name Contego
Manufacturer Iovance
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional remarks Autologous T cell therapy that utilizes tumor infiltrating lymphocytes (TILs) derived from the patient's tumor.

Registration

Registration route Centralised (EMA)
Particularity New medicine
Submission date 2018
Expected Registration 2019
Registration phase Clinical trials

Therapeutic value

Therapeutic value No judgement
References NCT02360579
Additional remarks NCT02360579: The cell transfer therapy used in this study involves patients receiving a lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

Expected patient volume per year

Patient volume

< 661

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks 661 patienten met Melanoom stadium III en IV

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.